Renaissance Technologies LLC Acquires 29,087 Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB)

Renaissance Technologies LLC lifted its holdings in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) by 44.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 94,711 shares of the biopharmaceutical company's stock after buying an additional 29,087 shares during the quarter. Renaissance Technologies LLC owned about 1.49% of Assembly Biosciences worth $1,495,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. JPMorgan Chase & Co. grew its holdings in Assembly Biosciences by 5,137.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company's stock worth $53,000 after acquiring an additional 3,442 shares during the period. Palumbo Wealth Management LLC acquired a new stake in shares of Assembly Biosciences during the fourth quarter worth $180,000. Monimus Capital Management LP bought a new stake in Assembly Biosciences in the fourth quarter valued at about $664,000. Finally, Peapod Lane Capital LLC acquired a new position in Assembly Biosciences in the fourth quarter valued at about $994,000. 19.92% of the stock is owned by institutional investors.

Assembly Biosciences Stock Up 24.0 %

Shares of ASMB traded up $2.74 on Friday, hitting $14.18. The company's stock had a trading volume of 83,750 shares, compared to its average volume of 26,105. The firm has a market capitalization of $108.31 million, a price-to-earnings ratio of -2.11 and a beta of 0.65. The firm's fifty day moving average price is $10.58 and its 200-day moving average price is $13.70. Assembly Biosciences, Inc. has a fifty-two week low of $7.75 and a fifty-two week high of $19.93.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.75) by $0.18. The company had revenue of $7.36 million during the quarter, compared to the consensus estimate of $7.05 million. Assembly Biosciences had a negative net margin of 144.05% and a negative return on equity of 121.46%. As a group, equities analysts predict that Assembly Biosciences, Inc. will post -6.87 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on ASMB. StockNews.com cut Assembly Biosciences from a "buy" rating to a "hold" rating in a research note on Monday, March 24th. HC Wainwright reiterated a "neutral" rating on shares of Assembly Biosciences in a report on Monday, March 24th. Finally, Guggenheim started coverage on shares of Assembly Biosciences in a report on Tuesday, March 25th. They issued a "buy" rating and a $31.00 price target for the company.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.